Your browser is no longer supported. Please, upgrade your browser.
PolyPid Ltd.
Index- P/E- EPS (ttm)-1.78 Insider Own13.71% Shs Outstand18.75M Perf Week-4.22%
Market Cap134.69M Forward P/E- EPS next Y-2.36 Insider Trans0.00% Shs Float16.18M Perf Month-9.64%
Income-33.20M PEG- EPS next Q-0.62 Inst Own19.40% Short Float0.11% Perf Quarter-2.90%
Sales- P/S- EPS this Y-420.40% Inst Trans- Short Ratio0.65 Perf Half Y-25.69%
Book/sh3.03 P/B2.32 EPS next Y-7.10% ROA-46.00% Target Price23.86 Perf Year-37.23%
Cash/sh2.49 P/C2.82 EPS next 5Y- ROE-48.20% 52W Range6.95 - 16.50 Perf YTD-28.99%
Dividend- P/FCF- EPS past 5Y-20.50% ROI- 52W High-56.24% Beta-
Dividend %- Quick Ratio11.40 Sales past 5Y- Gross Margin- 52W Low3.88% ATR0.35
Employees57 Current Ratio11.40 Sales Q/Q- Oper. Margin- RSI (14)41.40 Volatility3.79% 4.53%
OptionableYes Debt/Eq0.00 EPS Q/Q50.10% Profit Margin- Rel Volume1.17 Prev Close7.03
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume26.77K Price7.22
Recom1.80 SMA20-4.13% SMA50-8.95% SMA200-21.51% Volume23,074 Change2.70%
Sep-14-21Initiated JMP Securities Mkt Outperform $14
Jul-30-21Initiated Cantor Fitzgerald Overweight $24
Nov-24-20Upgrade Raymond James Outperform → Strong Buy
Aug-10-20Initiated Alliance Global Partners Buy $27
Jul-21-20Initiated Raymond James Outperform $23
Jul-21-20Initiated BMO Capital Markets Outperform $30
Jul-21-20Initiated Barclays Overweight $22
Sep-27-21 02:08PM  
Sep-20-21 07:00AM  
Sep-13-21 11:00AM  
Aug-17-21 08:00AM  
Aug-11-21 07:00AM  
Aug-09-21 08:00AM  
Jul-28-21 07:00AM  
Jul-12-21 08:00AM  
Jun-28-21 09:30AM  
Jun-23-21 06:30AM  
Jun-22-21 09:58PM  
Jun-02-21 09:10AM  
May-19-21 12:51PM  
May-12-21 07:00AM  
Apr-29-21 07:00AM  
Mar-29-21 08:33AM  
Feb-23-21 07:30AM  
Feb-16-21 07:31AM  
Feb-10-21 07:34AM  
Jan-27-21 07:30AM  
Dec-22-20 07:00AM  
Dec-16-20 07:00AM  
Dec-03-20 08:00AM  
Nov-24-20 08:17AM  
Nov-11-20 06:30AM  
Nov-04-20 08:45AM  
Oct-28-20 07:00AM  
Oct-14-20 10:29AM  
Sep-28-20 01:28PM  
Aug-19-20 07:00AM  
Aug-05-20 04:01PM  
Aug-03-20 07:00AM  
Jul-27-20 07:00AM  
Jul-01-20 09:00AM  
Jun-30-20 04:01PM  
Jun-26-20 02:04AM  
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.